RATINGS CHANGES

Alexion (ALXN - Get Report) was upgraded to overweight from equal-weight at Barclays. $155 price target. The company has multiple potential catalysts for 2017, Barclays said. 

Bob Evans (BOBE) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: BOBE.

Delphi (DLPH - Get Report) was downgraded to underweight from overweight at Morgan Stanley. $59 price target. The company is seeing slower growth and realizing lower margins, given increased competition, Morgan Stanley said. 

Darden Restaurants (DRI - Get Report) was downgraded to neutral from outperform at Credit Suisse. The valuation is less attractive, based on a $72 price target, Credit Suisse said. 

Greif (GEF - Get Report) was downgraded to equal-weight from sector weight at Keybanc. $47 price target. Organic sales growth will likely remain weak and currency should be a drag in 2017, Keybanc said. 

Goldman Sachs (GS - Get Report) was downgraded to neutral at Nomura. The valuation is less attractive, following the recent rally, Nomura said. 

Johnson & Johnson (JNJ - Get Report) was downgraded to equal-weight from overweight at Barclays. The valuation is less attractive, based on a $125 price target, Barclays said. 

Pfizer (PFE - Get Report) was upgraded to overweight from equal-weight at Barclays. $38 price target. The company should be able to use foreign cash to boost returns and the oncology business will drive growth, Barclays said. 

Vertex Pharmaceuticals (VRTX - Get Report) was downgraded to equal-weight from overweight at Barclays $90 price target. The company has an uncertain clinical profile, Barclays said.  

U.S. Steel (X - Get Report) was upgraded to hold at TheStreet Ratings. You can view the full analysis from the report here: X.

This article was written by a staff member of TheStreet.